News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

ProLynx Publishes Results Of Ultralong Half-Life PEG-SN38 Pro-Drug With Lower Intestinal Toxicity


3/28/2014 8:30:32 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

SAN FRANCISCO, March 27, 2014 (GLOBE NEWSWIRE) -- ProLynx LLC today announced a publication in the Journal of Medicinal Chemistry on macromolecular pro-drugs that provide the irinotecan active-metabolite SN-38 with ultralong half-life, low Cmax, and low glucuronide formation. These macromolecular pro-drugs have unique pharmacokinetic profiles that may translate to less intestinal toxicity and interpatient variability than the SN-38 pro-drugs thus far studied.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire

comments powered by Disqus
ProLynx
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES